Sangamo Therapeutics (NASDAQ:SGMO) appointed Dr. Bettina Cockroft as SVP and CMO to oversee clinical development activities and operations.
Sangamo is using its ex vivo gene-edited cell therapies and in vivo genome editing gene therapies to treat inherited metabolic, central nervous system and immunological diseases.
“This is an important time to welcome Dr. Cockroft to Sangamo, as we expect a steady flow of readouts from our ongoing clinical trials and expect to initiate additional trials in the coming year,” Adrian Woolfson, Sangamo’s EVP, research and development, said in a statement.
“We look forward to Dr. Cockroft’s contributions and believe she will be a key player in helping us realize our mission of translating our ground-breaking science into genomic medicines that transform patients’ lives,” he added.
Dr. Cockroft has 23 years of experience in the biopharmaceutical industry. She was most recently a member of the senior leadership team at Cytokinetics (NASDAQ:CYTK) and previously served as CMO of Auris Medical (NASDAQ:EARS).